- Home
- CHRO vs COSM Comparison
CHRO vs COSM Comparison
Compare CHRO & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- COSM
- Stock Information
- Founded
- CHRO 2002
- COSM 2009
- Country
- CHRO United States
- COSM Greece
- Employees
- CHRO N/A
- COSM N/A
- Industry
- CHRO
- COSM Other Pharmaceuticals
- Sector
- CHRO
- COSM Health Care
- Exchange
- CHRO Nasdaq
- COSM Nasdaq
- Market Cap
- CHRO 8.4M
- COSM 8.2M
- IPO Year
- CHRO 2024
- COSM 2013
- Fundamental
- Price
- CHRO $0.95
- COSM $0.45
- Analyst Decision
- CHRO Strong Buy
- COSM
- Analyst Count
- CHRO 1
- COSM 0
- Target Price
- CHRO N/A
- COSM N/A
- AVG Volume (30 Days)
- CHRO 2.1M
- COSM 814.2K
- Earning Date
- CHRO 05-13-2025
- COSM 05-15-2025
- Dividend Yield
- CHRO N/A
- COSM N/A
- EPS Growth
- CHRO N/A
- COSM N/A
- EPS
- CHRO N/A
- COSM N/A
- Revenue
- CHRO N/A
- COSM $54,426,402.00
- Revenue This Year
- CHRO N/A
- COSM $28.14
- Revenue Next Year
- CHRO N/A
- COSM N/A
- P/E Ratio
- CHRO N/A
- COSM N/A
- Revenue Growth
- CHRO N/A
- COSM 1.97
- 52 Week Low
- CHRO $0.45
- COSM $0.28
- 52 Week High
- CHRO $3.80
- COSM $1.58
- Technical
- Relative Strength Index (RSI)
- CHRO 35.68
- COSM 53.31
- Support Level
- CHRO $0.91
- COSM $0.40
- Resistance Level
- CHRO $1.14
- COSM $0.50
- Average True Range (ATR)
- CHRO 0.12
- COSM 0.06
- MACD
- CHRO -0.01
- COSM 0.01
- Stochastic Oscillator
- CHRO 17.04
- COSM 46.91
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.